8-K Announcements
6Material company update
May 8, 2026·SEC
Material company update
Apr 13, 2026·SEC
Material company update
Feb 27, 2026·SEC
CG Oncology, Inc. Common stock(CGON)Earnings, Financials & Key Ratios
CGON•NASDAQ
Price updated Jun 19, 2026
AboutCG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.Show more
- Revenue$4M+254.7%
- EBITDA-$189M-65.2%
- Net Income-$161M-82.9%
- EPS (Diluted)-2.08-47.5%
- Gross Margin-15.02%-115.0%
- EBITDA Margin-4686.36%+53.4%
- Operating Margin-4722.13%+53.1%
- Net Margin-3985.02%+48.4%
- ROE-21.67%-13.0%
CGON Key Insights
CG Oncology, Inc. Common stock (CGON) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Shares diluted 23.7% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CGON posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CGON Price & Volume
CG Oncology, Inc. Common stock (CGON) stock price & volume — 10-year historical chart
Loading chart...
CGON Growth Metrics
CG Oncology, Inc. Common stock (CGON) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years176.56%
TTM666.01%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-76.91%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-53.95%
Return on Capital
10 Years-29.49%
5 Years-29.49%
3 Years-28.48%
Last Year-25.54%
CGON Recent Earnings
CG Oncology, Inc. Common stock (CGON) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/8 qtrs (25%)●Beat Revenue 4/8 qtrs (80%)
Q2 2026Latest
May 8, 2026Metric
Actual
Est
EPS
$0.71-22.4%
$0.58
Rev
$1M+139.1%
$453,034
Q1 2026
Feb 27, 2026Metric
Actual
Est
EPS
$0.51+16.4%
$0.61
Rev
$2M+412.9%
$450,538
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$0.57-2.0%
$0.56
Rev
$2M+2706.4%
$59,364
Q3 2025
Aug 8, 2025Metric
Actual
Est
EPS
$0.54-10.2%
$0.49
Rev
—
$81,620
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 8, 2026 | $0.71vs $0.58-22.4% | $1Mvs $453,034+139.1% |
| Q1 2026 | Feb 27, 2026 | $0.51vs $0.61+16.4% | $2Mvs $450,538+412.9% |
| Q4 2025 | Nov 14, 2025 | $0.57vs $0.56-2.0% | $2Mvs $59,364+2706.4% |
| Q3 2025 | Aug 8, 2025 | $0.54vs $0.49-10.2% | —vs $81,620 |
Based on last 8 quarters of dataView full earnings history →
CGON Peer Comparison
CG Oncology, Inc. Common stock (CGON) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 GRVY | 455.29M | 65.52 | 10.19 | 11.92% | 17.92% | 7.95% | ||
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 TGTX | 8.15B | 53.22 | 19.21 | 87.32% | 65.95% | 87.36% | 0.40 | |
 JANX | 867.2M | 14.22 | -7.77 | -5.55% | -5.3% | -11.85% | 0.02 | |
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 IMCR | 1.45B | 28.60 | -53.96 | 20% | -4.88% | -4.83% | 0.11 | |
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 |
Compare CGON vs Peers
CG Oncology, Inc. Common stock (CGON) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CGON Income Statement
CG Oncology, Inc. Common stock (CGON) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|
Sales/Revenue | 10.36M | 191K | 204K | 1.14M | 4.04M | 5.07M |
Revenue Growth % | - | -98.16% | 6.81% | 458.33% | 254.7% | 666.01% |
Cost of Goods Sold | 10K | 15K | 0 | 0 | 4.65M | 7.45M |
COGS % of Revenue | 0.1% | 7.85% | - | - | 115.02% | - |
Gross Profit | 10.35M▲ 0% | 176K▼ 98.3% | 204K▲ 15.9% | 1.14M▲ 458.3% | -607K▼ 153.3% | -2.38M▲ 0% |
Gross Margin % | 99.9% | 92.15% | 100% | 100% | -15.02% | -46.97% |
Gross Profit Growth % | - | -98.3% | 15.91% | 458.33% | -153.29% | - |
Operating Expenses | 22.95M | 35.42M | 55.65M | 115.81M | 190.17M | 212.58M |
OpEx % of Revenue | 221.61% | 18545.55% | 27280.88% | 10167.25% | 4707.1% | - |
Selling, General & Admin | 4.63M | 6.39M | 9.9M | 33.7M | 73.53M | 79.52M |
SG&A % of Revenue | 44.75% | 3347.12% | 4853.43% | 2959% | 1819.95% | - |
Research & Development | 18.32M | 29.03M | 45.75M | 82.1M | 116.64M | 132.9M |
R&D % of Revenue | 176.86% | 15198.43% | 22427.45% | 7208.25% | 2887.15% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 155K |
Operating Income | -12.61M▲ 0% | -35.25M▼ 179.6% | -55.45M▼ 57.3% | -114.67M▼ 106.8% | -190.77M▼ 66.4% | -214.96M▲ 0% |
Operating Margin % | -121.7% | -18453.4% | -27180.88% | -10067.25% | -4722.13% | -4238.99% |
Operating Income Growth % | - | -179.6% | -57.32% | -106.8% | -66.37% | - |
EBITDA | -12.6M | -35.23M | -55.43M | -114.63M | -189.33M | -212.7M |
EBITDA Margin % | -121.61% | -18445.55% | -27172.55% | -10064.44% | -4686.36% | -4194.38% |
EBITDA Growth % | - | -179.7% | -57.34% | -106.8% | -65.16% | -58.28% |
D&A (Non-Cash Add-back) | 10K | 15K | 17K | 32K | 1.45M | 2.26M |
EBIT | -12.39M | -35.25M | -55.45M | -114.67M | -161M | -200.25M |
Net Interest Income | -451K | -1K | 6.9M | 26.62M | 0 | 43.52M |
Interest Income | 0 | 0 | 6.9M | 26.62M | 0 | 43.52M |
Interest Expense | 451K | 1K | 0 | 0 | 0 | 0 |
Other Income/Expense | -233K | -197K | 6.84M | 26.63M | 29.78M | 28.21M |
Pretax Income | -12.84M▲ 0% | -35.44M▼ 176.1% | -48.61M▼ 37.1% | -88.04M▼ 81.1% | -161M▼ 82.9% | -186.75M▲ 0% |
Pretax Margin % | -123.95% | -18556.54% | -23826.96% | -7729.5% | -3985.02% | -3682.61% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -12.84M▲ 0% | -35.44M▼ 176.1% | -48.61M▼ 37.1% | -88.04M▼ 81.1% | -161M▼ 82.9% | -186.75M▲ 0% |
Net Margin % | -123.95% | -18556.54% | -23826.96% | -7729.5% | -3985.02% | -3682.61% |
Net Income Growth % | - | -176.06% | -37.14% | -81.12% | -82.87% | -76.91% |
Net Income (Continuing) | -12.84M | -35.44M | -48.61M | -88.04M | -161M | -186.75M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.28▲ 0% | -0.66▼ 135.7% | -1.02▼ 54.5% | -1.41▼ 38.2% | -2.08▼ 47.5% | -2.21▲ 0% |
EPS Growth % | - | -135.71% | -54.55% | -38.24% | -47.52% | -53.95% |
EPS (Basic) | -0.28 | -0.66 | -1.02 | -1.41 | -2.08 | - |
Diluted Shares Outstanding | 66.64M | 66.64M | 66.64M | 62.5M | 77.3M | 84.52M |
Basic Shares Outstanding | 66.64M | 66.64M | 66.64M | 62.5M | 77.3M | 84.52M |
Dividend Payout Ratio | - | - | - | - | - | - |
CGON Balance Sheet
CG Oncology, Inc. Common stock (CGON) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|
Total Current Assets | 58.41M | 147.21M | 194.12M | 754.21M | 759.48M | 1.1B |
Cash & Short-Term Investments | 53.61M | 143.48M | 187.67M | 742M | 742.15M | 1.08B |
Cash Only | 53.61M | 88.14M | 8.27M | 257.07M | 32.49M | 33.7M |
Short-Term Investments | 0 | 55.34M | 179.41M | 484.93M | 709.66M | 1.04B |
Accounts Receivable | 2K | 303K | 92K | 781K | 688K | 1.27M |
Days Sales Outstanding | 0.07 | 579.03 | 164.61 | 250.28 | 62.16 | 54.7 |
Inventory | 0 | 0 | 0 | 0 | 1.56M | 1.49M |
Days Inventory Outstanding | - | - | - | - | 122.92 | 55.82 |
Other Current Assets | 4.8M | 3.42M | 6.36M | 11.43M | 15.07M | 23.13M |
Total Non-Current Assets | 285K | 539K | 5.18M | 587K | 32.12M | 33.12M |
Property, Plant & Equipment | 200K | 506K | 491K | 493K | 19.57M | 19.59M |
Fixed Asset Turnover | 51.79x | 0.38x | 0.42x | 2.31x | 0.21x | 0.34x |
Goodwill | 0 | 0 | 0 | 0 | 10.3M | 10.3M |
Intangible Assets | 0 | 0 | 0 | 0 | 575K | 560K |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 85K | 33K | 4.69M | 94K | 1.68M | 2.68M |
Total Assets | 58.69M▲ 0% | 147.75M▲ 151.7% | 199.3M▲ 34.9% | 754.8M▲ 278.7% | 791.59M▲ 4.9% | 1.14B▲ 0% |
Asset Turnover | 0.18x | 0.00x | 0.00x | 0.00x | 0.01x | 0.01x |
Asset Growth % | - | 151.73% | 34.89% | 278.72% | 4.87% | 117.19% |
Total Current Liabilities | 5.97M | 15.43M | 14.25M | 21.37M | 30.84M | 35.22M |
Accounts Payable | 1M | 985K | 3.24M | 6.52M | 5.71M | 8.24M |
Days Payables Outstanding | 36.61K | 23.97K | - | - | 448.81 | 370.58 |
Short-Term Debt | 2.94M | 8.97M | 569K | 0 | 915K | 1.07M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 259K |
Other Current Liabilities | 1.13M | 173K | 547K | 436K | 24.21M | 25.91M |
Current Ratio | 9.78x | 9.54x | 13.62x | 35.30x | 24.63x | 31.30x |
Quick Ratio | 9.78x | 9.54x | 13.62x | 35.30x | 24.58x | 31.25x |
Cash Conversion Cycle | - | - | - | - | -263.73 | -260.06 |
Total Non-Current Liabilities | 12.46M | 7.14M | 257K | 52K | 8.15M | 8.27M |
Long-Term Debt | 12.06M | 6.53M | 0 | 0 | 6.11M | 6.51M |
Capital Lease Obligations | 50K | 257K | 244K | 52K | 0 | 4.04M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 307K | 2.22M |
Other Non-Current Liabilities | 351K | 352K | 13K | 0 | 1.74M | 1.45M |
Total Liabilities | 18.44M | 22.57M | 14.51M | 21.42M | 38.99M | 43.48M |
Total Debt | 15.13M | 15.94M | 1.03M | 238K | 7.02M | 7.58M |
Net Debt | -38.48M | -72.2M | -7.24M | -256.83M | -25.47M | -26.13M |
Debt / Equity | 0.38x | 0.13x | 0.01x | 0.00x | 0.01x | 0.01x |
Debt / EBITDA | - | - | - | - | - | -0.04x |
Net Debt / EBITDA | - | - | - | - | - | 0.12x |
Interest Coverage | -27.47x | -35246.00x | - | - | - | - |
Total Equity | 40.25M▲ 0% | 125.18M▲ 211.0% | 184.79M▲ 47.6% | 733.38M▲ 296.9% | 752.6M▲ 2.6% | 1.09B▲ 0% |
Equity Growth % | - | 210.98% | 47.62% | 296.87% | 2.62% | 107.01% |
Book Value per Share | 0.60 | 1.88 | 2.77 | 11.73 | 9.74 | 12.92 |
Total Shareholders' Equity | 40.25M | 125.18M | 184.79M | 733.38M | 752.6M | 1.09B |
Common Stock | 0 | 0 | 0 | 8K | 8K | 9K |
Retained Earnings | -45.89M | -81.33M | -129.94M | -217.98M | -378.98M | -439.18M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
CGON Cash Flow Statement
CG Oncology, Inc. Common stock (CGON) cash flow — operating, investing & free cash flow history
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|
Cash from Operations | -13.65M | -29.8M | -45.68M | -78.71M | -132.35M | -160.01M |
Operating CF Margin % | -131.82% | -15604.19% | -22391.67% | -6910.71% | -3275.89% | - |
Operating CF Growth % | - | -118.28% | -53.26% | -72.32% | -68.14% | -387.54% |
Net Income | -12.84M | -35.44M | -48.61M | -88.04M | -161M | -186.75M |
Depreciation & Amortization | 10K | 15K | 17K | 32K | 1.45M | 2.26M |
Stock-Based Compensation | 1.11M | 676K | 1.53M | 11.4M | 26.68M | 21.52M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 30K | 509K | -2.06M | -5.01M | -1.75M | 6.92M |
Working Capital Changes | -1.97M | 4.44M | 3.44M | 2.91M | 2.28M | -3.97M |
Change in Receivables | 0 | 0 | 0 | -689K | -320K | -1.34M |
Change in Inventory | 0 | 0 | 0 | 0 | -444K | 8K |
Change in Payables | 578K | -18K | 2.01M | 3.27M | -1.64M | 664K |
Cash from Investing | -97K | -55.35M | -121.19M | -300.76M | -245.82M | -393.9M |
Capital Expenditures | -97K | -14K | 0 | -234K | -134K | -422K |
CapEx % of Revenue | 0.94% | 7.33% | - | 20.54% | 3.32% | 8.32% |
Acquisitions | 0 | 0 | 0 | 0 | -21.97M | -21.97M |
Investments | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 25M |
Cash from Financing | 15.45M | 119.69M | 87M | 628.28M | 153.59M | 546.14M |
Debt Issued (Net) | 15.2M | 0 | -16.29M | -365K | 0 | 0 |
Equity Issued (Net) | 245K | 119.69M | 104.63M | 629.47M | 153.59M | 540.94M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | -1.34M | -825K | 0 | 5.2M |
Net Change in Cash | 1.7M▲ 0% | 34.54M▲ 1937.5% | -79.88M▼ 331.3% | 248.8M▲ 411.5% | -224.58M▼ 190.3% | -7.77M▲ 0% |
Free Cash Flow | -13.75M▲ 0% | -29.82M▼ 116.8% | -45.68M▼ 53.2% | -78.95M▼ 72.8% | -132.48M▼ 67.8% | -160.43M▲ 0% |
FCF Margin % | -132.76% | -15611.52% | -22391.67% | -6931.26% | -3279.21% | -3163.75% |
FCF Growth % | - | -116.84% | -53.19% | -72.83% | -67.81% | -95.14% |
FCF per Share | -0.21 | -0.45 | -0.69 | -1.26 | -1.71 | -1.90 |
FCF Conversion (FCF/Net Income) | 1.06x | 0.84x | 0.94x | 0.89x | 0.82x | 0.86x |
Interest Paid | 0 | 0 | 376K | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
CGON Key Ratios
CG Oncology, Inc. Common stock (CGON) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
Return on Equity (ROE) | -42.85% | -31.36% | -19.18% | -21.67% | -23.33% |
Return on Invested Capital (ROIC) | -96.56% | -36.08% | -26.3% | -23.77% | -20.81% |
Gross Margin | 92.15% | 100% | 100% | -15.02% | -46.97% |
Net Margin | -18556.54% | -23826.96% | -7729.5% | -3985.02% | -3682.61% |
Debt / Equity | 0.13x | 0.01x | 0.00x | 0.01x | 0.01x |
Interest Coverage | -35246.00x | - | - | - | - |
FCF Conversion | 0.84x | 0.94x | 0.89x | 0.82x | 0.86x |
Revenue Growth | -98.16% | 6.81% | 458.33% | 254.7% | 666.01% |
Related:CGON Dividend History·CGON Revenue History·CGON Price History·CGON P/E History·CGON Financial Ratios·CGON Institutional Holders
CGON SEC Filings & Documents
CG Oncology, Inc. Common stock (CGON) SEC filings — annual & quarterly reports (10-K, 10-Q)
CGON Frequently Asked Questions
CG Oncology, Inc. Common stock (CGON) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
CG Oncology, Inc. Common stock (CGON) reported $5.1M in revenue for fiscal year 2025. This represents a 51% decrease from $10.4M in 2021.
CG Oncology, Inc. Common stock (CGON) grew revenue by 254.7% over the past year. This is strong growth.
CG Oncology, Inc. Common stock (CGON) reported a net loss of $186.7M for fiscal year 2025.
Dividend & Returns
CG Oncology, Inc. Common stock (CGON) has a return on equity (ROE) of -21.7%. Negative ROE indicates the company is unprofitable.
CG Oncology, Inc. Common stock (CGON) had negative free cash flow of $160.4M in fiscal year 2025, likely due to heavy capital investments.